Data / Form D filings / OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc.: Form D filings
OnKure Therapeutics, Inc., a pharmaceuticals company in Boulder, CO, filed 4 Form D notices with the SEC between 2018 and 2024. The latest, on October 21, 2024, reports $65 million sold of a $65 million offering to 20 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 6707 WINCHESTER CIRCLE, SUITE 400, Boulder, CO, 80301
- Phone
- (720) 307-2892
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1637715
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 21, 2024 | New notice | $65,000,000 | $65,000,000 | 20 | Oct 4, 2024 | sec.gov | |
| Dec 21, 2020 | New notice | $94,769,998 | $47,384,999 | $47,384,999 | 15 | Dec 9, 2020 | sec.gov |
| May 14, 2019 | New notice | $25,000,002 | $25,000,002 | 9 | May 1, 2019 | sec.gov | |
| Jan 8, 2018 | New notice | $51,994,684 | $21,994,682 | $30,000,002 | 16 | Dec 22, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Isaac M. Manke | Director | |
| Jason Leverone | Executive Officer | |
| Samuel Agresta | Executive Officer | |
| Dylan Hartley | Executive Officer | |
| Edward T. Mathers | Director | |
| Nicholas Saccomano | Executive Officer, Director | |
| Valerie M. Jansen | Director | |
| R. Michael Carruthers | Director | |
| Michael G. Grey | Director | |
| Andrew Johm Phillips | Director |
Every Form D from the week of Oct 21, 2024 · All recent filings in Colorado · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what OnKure Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.